摘要
肺癌是当今世界最常见的恶性肿瘤之一,其发病率和死亡率居我国恶性肿瘤之首,大多数肺癌患者临床确诊时已发生远处转移,错失治疗的最佳时机,因此,对肺癌患者进行早期诊断和治疗极其重要。动态对比增强磁共振成像(DCE-MRI)作为一种新型的非侵袭性成像方法,能够在体监测肿瘤血管的功能状态,对肺癌患者的诊断、鉴别诊断和药物疗效进行个体化评估。本文主要针对DCE-MRI在肺癌诊断、鉴别诊断和药物疗效评估等方面的应用进行综述。
引文
[1] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2] Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.
[3] van den Boogaart VE,de Lussanet QG,Houben RM,et al.Interreader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib[J].Lung Cancer,2016,93(3):20-27.
[4] de Langen AJ,van den Boogaart V,Lubberink M,et al.Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI[J].J Nucl Med,2011,52(1):48-55.
[5] Nishino M,Hatabu H,Johnson BE,et al.State of the art:response assessment in lung cancer in the era of genomic medicine[J].Radiology,2014,271(1):6-27.
[6]张倩倩,陆普选.HIV相关神经认知疾病的功能磁共振成像研究进展[J].新发传染病电子杂志,2016,1(1):56-59.
[7] Khalifa F,Soliman A,El-Baz A,et al.Models and methods for analyzing DCE-MRI:A review[J].Med Phys,2014,41(12):124301.
[8] Nielsen T,Wittenborn T,Horsman MR.Dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI)in preclinical studies of antivascular treatments[J].Pharmaceutics,2012,4(4):563-589.
[9] Koh TS,Bisdas S,Koh DM,et al.Fundamentals of tracer kinetics for dynamic contrast-enhanced MRI[J].J Magn Reson Imaging,2011,34(6):1262-1276.
[10] Teo QQ,Thng CH,Koh TS,et al.Dynamic contrast-enhanced magnetic resonance imaging:applications in oncology[J].Clin Oncol(R Coll Radiol),2014,26(10):9-20.
[11] Rogers MS,Novak K,Zurakowski D,et al.Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors[J].Mol Cancer Res,2014,12(5):754-764.
[12] Ewing JR,Bagher-Ebadian H.Model selection in measures of vascular parameters using dynamic contrast enhanced MRI:experimental and clinical applications[J].NMR Biomed,2013,26(8):1028-1041.
[13] Sourbron SP,Buckley DL.Classic models for dynamic contrastenhanced MRI[J].NMR Biomed,2013,26(8):1004-1027.
[14]库雷志,马明平,俞顺,等DCE-MRI在肺癌不同病理类型的诊断价值[J].中国医学影像学杂志,2016,24(2):100-105.
[15] Cheng Z,Wu Z,Shi G,et al.Discrimination between benign and malignant breast lesions using volumetric quantitative dynamic contrast-enhanced MR imaging[J].Eur Radiol,2018,28(3):982-991.
[16] Li X,Hu JL,Zhu LM,et al.The clinical value of dynamic contrast-enhanced MRI in differential diagnosis of malignant and benign ovarian lesions[J].Tumour Biol,2015,36(7):5515-5522.
[17]李智勇,张婷婷,李梦颖,等.动态增强磁共振成像在孤立性富血供肺结节良恶性鉴别诊断中的临床研究[J].CT理论与应用研究,2012,21(3):563-570.
[18] Gupta N,Sureka B,Kumar MM,et al.Comparison of dynamic contrast-enhanced and diffusion weighted magnetic resonance image in staging and grading of carcinoma bladder with histopathological correlation[J].Urol Ann,2015,7(2):199-204.
[19] Kim SH,Choi MS,Kim MJ,et al.Role of semi-quantitative dynamic contrast-enhanced MR imaging in characterization and grading of prostate cancer[J].Eur J Radiol,2017,94(9):154-159.
[20] Kim SH,Lee JM,Gupta SN,et al.Dynamic contrast-enhanced MRI to evaluate the therapeutic response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer[J].J Magn Reson Imaging,2014,40(3):730-737.
[21] Fujimoto K,Abe T,Muller NL,et al.Small peripheral pulmonary carcinomas evaluated with dynamic MR imaging:correlation with tumor vascularity and prognosis[J].Radiology,2003,227(3):786-793.
[22] Kono R,Fujimoto K,Terasaki H,et al.Dynamic MRI of solitary pulmonary nodules:comparison of enhancement patterns of malignant and benign small peripheral lung lesions[J].AJR,2012,188(1):26-36.
[23] Zou Y,Zhang M,Wang Q,et al.Quantitative investigation of solitary pulmonary nodules:dynamic contrast-enhanced MRI and histopathologic analysis[J].AJR,2008,191(1):252-259.
[24]马晓玲,周舒畅,艾涛,等.动态增强磁共振在肺孤立性结节灶中的定量化研究[J].放射学实践,2014,29(10):1158-1162.
[25] Schaefer JF,Schneider V,Vollmar J,et al.Solitary pulmonary nodules:association between signal characteristics in dynamic contrast enhanced MRI and tumor angiogenesis[J].Lung Cancer,2006,53(1):39-49.
[26] Schaefer JF,Vollmar J,Schick F,et al.Solitary pulmonary nodules:dynamic contrast-enhanced MR imaging——perfusion differences in malignant and benign lesions[J].Radiology,2004,232(2):544-553.
[27] Türkbey B,Thomasson D,Pang Y,et al.The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment[J].Diagn Interv Radiol,2010,16(3):186-192.
[28] Burger RA,Brady MF,Bookman MA,et al.Incorporation of bevacizumab in the primary treatment of ovarian cancer[J].N Engl J Med,2011,365(26):2473-2483.
[29] Escudier B,Bellmunt J,Négrier S,et al.PhaseⅢtrial of bevacizumab plus interferon alfa-2ain patients with metastatic renal cell carcinoma(AVOREN):final analysis of overall survival[J].J Clin Oncol,2010,28(13):2144-2150.
[30] Spigel DR,Townley PM,Waterhouse DM,et al.Randomized Phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer:results from the SALUTE trial[J].J Clin Oncol,2011,29(16):2215-2222.
[31] Tewari KS,Sill MW,Long HJ,et al.Improved survival with bevacizumab in advanced cervical cancer[J].N Engl J Med,2014,370(8):734-743.
[32] Muruganandham M,Lupu M,Dyke JP,et al.Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501by dynamic contrast-enhanced MRI at 1.5T[J].Mol Cancer Ther,2006,5(8):1950-1957.
[33] Li X,Wang H,Ding S,et al.Evaluating the effectiveness of Endostar therapy in human lung cancer xenografts using contrastenhanced magnetic resonance imaging[J].Int J Clin Exp Med,2016,9(7):13059-13064.
[34] Koo HJ,Lee M,Kim J,et al.Synergistic effect of anti-angiogenic and radiation therapy:quantitative evaluation with dynamic contrast enhanced MR imaging[J].Plos One,2016,11(2):e0148784.
[35] Nensa F,Stattaus J,Morgan B,et al.Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer[J].Future Oncol,2014,10(5):823-833.
[36] Dingemans AM,de Langen AJ,van den Boogaart V,et al.Firstline erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer:aphase II study including molecular imaging[J].Ann Oncol,2011,22(3):559-566.
[37] Kelly RJ,Rajan A,Force J,et al.Evaluation of KRAS mutations,angiogenic biomarkers,and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib[J].Clin Cancer Res,2011,17(5):1190-1199.
